









Markets
/
Stocks
/
nasdaq-kod
/

Kodiak Sciences Inc

KOD

9.840USD

+0.630+6.84%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

519.77MMarket Cap

LossP/E TTM



Kodiak Sciences Inc

9.840

+0.630+6.84%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

235 / 506

Overall Ranking

386 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Hold

Current Rating

4.667

Target Price

-49.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Undervalued

The company’s latest PE is -2.60, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 46.04M shares, decreasing 15.85% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.82M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.17.

Financial Health

Currency: USD Updated: 2025-09-18

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.43, which is -57.05% below the recent high of -1.04 and 16.12% above the recent low of -2.04.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 235/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 5.60, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Kodiak Sciences Inc is 5.00, with a high of 7.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

5.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Hold

Current Rating

4.667

Target Price

-49.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Kodiak Sciences Inc

KOD

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 7.13, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 10.46 and the support level at 8.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.13

Change

1.75

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.218

Neutral

RSI(14)

56.733

Neutral

STOCH(KDJ)(9,3,3)

46.948

Neutral

ATR(14)

0.738

High Vlolatility

CCI(14)

38.899

Neutral

Williams %R

33.476

Buy

TRIX(12,20)

0.460

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

9.396

Buy

MA10

9.700

Buy

MA20

9.457

Buy

MA50

8.210

Buy

MA100

6.040

Buy

MA200

5.863

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 87.25%, representing a quarter-over-quarter decrease of 0.60%. The largest institutional shareholder is The Vanguard, holding a total of 1.82M shares, representing 3.45% of shares outstanding, with 7.92% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

17.31M

Perlroth (Victor D)

2.70M

+24.31%

BlackRock Institutional Trust Company, N.A.

2.83M

-0.75%

Adage Capital Management, L.P.

1.33M

+16.34%

Acadian Asset Management LLC

1.95M

+27.01%

The Vanguard Group, Inc.

Star Investors

1.69M

+0.39%

ICONIQ Capital, LLC

1.27M

+24.56%

TCG Crossover Management, LLC

1.15M

State Street Global Advisors (US)

849.25K

+2.18%

Geode Capital Management, L.L.C.

793.59K

+3.24%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.02, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.54. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.